Madrigal Pharmaceuticals MDGL is preparing to release its quarterly earnings on Thursday, 2024-10-31. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Madrigal Pharmaceuticals to report an earnings per share (EPS) of $-7.09.
The announcement from Madrigal Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Overview of Past Earnings
In the previous earnings release, the company beat EPS by $0.44, leading to a 4.08% increase in the share price the following trading session.
Here's a look at Madrigal Pharmaceuticals's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -7.54 | -6.28 | -5.28 | -4.92 |
| EPS Actual | -7.10 | -7.38 | -5.68 | -5.34 |
| Price Change % | 4.0% | -5.0% | -7.000000000000001% | 3.0% |
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
